Spyre Therapeutics, a biotechnology company, announced a public offering of 14,864,865 shares of common stock at $18.50 per share, totaling approximately $275.0 million. The offering is expected to close on October 15, 2025. Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are the joint book-running managers for the offering. Spyre Therapeutics aims to advance antibody engineering for Inflammatory Bowel Disease and other immune-mediated diseases. The company’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. The offering is subject to customary closing conditions and regulatory approval.

Read more at GlobeNewswire: Spyre Therapeutics Announces Pricing of $275.0 Million